Arginine
Active ingredient
Sold as LysaKare · D-87 · A L O Formula · VITAL II
- Drug class
- -
- Availability
- Over-the-counter
- Routes
- Oral, Sublingual
- Markets covered
- 3
- Products on record
- 7
- FDA reports (12 mo)
- 62
Overview
Plain-language summary, compiled from the cited regulatory records
Arginine is an ingredient used in products that temporarily relieve symptoms associated with aging and/or a run-down condition [1]. These symptoms include low energy, poor muscle/fat balance, and occasional sleeplessness [1].
This ingredient is available under various brand names, including VITAL II, A L O Formula, and D-87 [1]. In the past 12 months, there have been 62 adverse event reports associated with products containing this ingredient [2]. The most frequently reported reactions include atrial fibrillation, diarrhea, eye pain, pain, and cardiac disorder [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 4 | January 8, 2026 |
| GB United Kingdom | MHRA | 2 | May 1, 2026 |
| EU European Union | EMA | 1 | April 1, 2026 |
USUnited States· FDA
4 products
Uses
USES:
Temporarily relieves these symptoms due to aging and/or a run-down condition: • low energy • poor muscle/fat balance • occasional sleeplessness
How to take
GBUnited Kingdom· MHRA
2 products
Uses
TRIOMEL PERIPHERAL is indicated for parenteral nutrition for adults and children greater than 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
How to take
EUEuropean Union· EMA
1 product
Uses
LysaKare is indicated for reduction of renal radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.
How to take
Sources & citations
- [1]FDA DailyMed · 04cded9a-0431-4e… · revised July 1, 2024 [PDF]
- [2]MHRA (UK) · PL001160643 · revised June 20, 2025
- [3]European Medicines Agency · EMEA/H/C/004541 · revised April 1, 2026
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.